학술논문

Biomarkers of intestinal permeability and blood-brain barrier permeability in adolescents with major depressive disorder.
Document Type
Article
Source
Journal of Affective Disorders. Feb2023, Vol. 323, p659-666. 8p.
Subject
*MENTAL depression
*BLOOD-brain barrier
*TEENAGERS
*PERMEABILITY
*MENTAL illness
Language
ISSN
0165-0327
Abstract
The etiology in major depressive disorder (MDD) has not been fully understood. Accumulating evidence suggests an association between altered intestinal and blood-brain barrier (BBB) permeability and psychiatric disorders, while its changes in adolescent MDD populations have been received less attention. In this study, our aim was to explore the differences in plasma levels of intestinal and blood-brain barrier permeability markers in adolescents with MDD compared with healthy controls (HCs). We enrolled MDD (n = 50), and HCs (n = 40) with the age of 13–18 years old. The plasma level of zonulin, I-FABP, LPS, and claudin-5 were quantified. The Hamilton Depression Scale 17 items (HAMD-17) and Hamilton Anxiety Scale 14 items (HAMA-14) were used for symptom assessments. The plasma levels of zonulin, I-FABP, LPS, and claudin-5 in the MDD group were significantly higher than those in the HCs. Plasma I-FABP levels in MDD with moderate to severe anxiety were significantly higher than those in MDD without moderate to severe anxiety and HCs. In addition, these four biomarkers (alone or combined) can be used as diagnostic markers for MDD in adolescents. The key limitation of this study is the blood measurements at a single time point with a relatively small sample size. These findings advance our understanding of the pathophysiology of intestinal barrier injury, bacterial translocation, and blood-brain barrier injury involved in adolescents with MDD. • This is the first study to compare plasma levels of Zonulin, I-FABP, LPS, and Claudin-5 in adolescent MDD patients with healthy controls. • The plasma concentration of Zonulin, I-FABP, LPS, and Claudin-5 levels were significantly elevated in adolescent MDD patients compared to healthy controls. • In the subgroup analysis of anxiety, plasma I-FABP levels were significantly higher in MDD patients with moderate to severe anxiety. • The ROC curve analysis of these four biomarkers revealed each one can be used to individually distinguish MDD patients from healthy controls, but the largest AUC was when the four biomarkers (Zonulin, I-FABP, LPS, and Claudin-5) were used in combination. [ABSTRACT FROM AUTHOR]